Uni-Bio Science Group Limited (0690)

Overview

Uni-Bio Science Group Limited is a pioneering investment holding entity engaged in the discovery, development, manufacturing, and commercialization of a wide range of biological and chemical pharmaceutical products. Specifically focused on addressing various human diseases, the company operates within the boundary of the People’s Republic of China. It boasts a diverse portfolio, delineated into three major segments: Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. Established in 2001, Uni-Bio Science Group Limited has its headquarters situated in Sha Tin, Hong Kong. The company stands at the forefront of innovation in the pharmaceutical sector, positioning itself as a key player in advancing healthcare solutions within China’s vast market.

Products and Services

• GeneTime

  A flagship prescription biological drug primarily designed for wound healing. GeneTime utilizes advanced biomedical research to promote efficient and effective recovery of various types of wounds, marking significant progress in medical treatments related to skin regeneration and recovery.

• GeneSoft

  Targeting ocular health, GeneSoft serves as a therapeutic drug for conditions such as dry eye syndrome, corneal damage, and aids in the healing process post-operative procedures. By addressing these common yet distressing eye conditions, GeneSoft provides a critical solution in the sphere of ophthalmic care.

• Pinup

  A powerful voriconazole tablet engineered to combat severe fungal infections. Pinup's formulation allows for effective treatment against a range of fungal threats, safeguarding patients with compromised immune systems or those at risk of invasive fungal diseases.

• Boshutai

  As a small molecule drug, Boshutai is designed to combat diabetes. Offering a new lease of life for individuals battling this chronic condition, Boshutai exemplifies Uni-Bio Science Group’s commitment to fighting one of the most prevalent global health crises.

• Prescription Drugs in Development

  The company is actively engaged in the development of advanced prescription drugs, introducing innovations like rExendin-4 (Uni-E4) for Type 2 diabetes, rhPTH 1-34 (Uni-PTH) aimed at treating osteoporosis in postmenopausal women, and Uni-GLP, a GLP-1 agent designed for the management of Type 2 diabetes. These pipeline products underscore the company’s dedication to addressing a broad spectrum of human diseases through cutting-edge research and development.